Linnea Achieves CEP Certification for Cannabidiol Isolate
3.3.2026 09:25:00 EET | Business Wire | Press release
Linnea is proud to announce that its Cannabidiol (CBD) Isolate has been granted a Certificate of Suitability to the European Pharmacopoeia (CEP).
The CEP serves to attest that the quality of an active pharmaceutical ingredient (API) is adequately controlled by the monographs of the European Pharmacopoeia, ensuring its safety, quality and conformity for use in medicinal products in Europe.
Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), the CEP represents an independent validation of consistency, safety, and regulatory compliance for the European market. This consequently simplifies the marketing authorization (MA) process for new medicines, as a detailed evaluation of the active substance by regulatory authorities is not required.
This milestone represents a significant achievement for the company and reinforces its commitment to delivering consistent and high-quality cannabinoid ingredients. The certification provides customers and partners with assurance regarding product quality, regulatory compliance, and manufacturing expertise.
“This achievement reflects our unwavering focus on quality, transparency, and regulatory excellence,” said Giorgia Tossi, Chief Quality Officer - Technical Responsible/QP. “We are grateful to our teams whose dedication made this milestone possible, and to our customers who continue to place their trust in us.”
With this certification, Linnea strengthens its position as a trusted supplier of premium cannabinoid ingredients and continues its journey towards enhanced global compliance and quality leadership.
ABOUT LINNEA
Founded in 1982, Linnea is a Swiss-based manufacturer of premium botanical active ingredients for the pharmaceutical, nutraceutical, and cosmetic industries. Operating from a GMP-certified facility, the company is also a leader in medical cannabinoids, applying a pharma-driven, approach to cannabinoid development. Serving over 300 clients in more than 50 countries, Linnea combines regulatory expertise, scientific excellence, and tailored support to deliver high-quality, compliant solutions worldwide.
www.linnea.ch
www.linneacannabinoids.ch
View source version on businesswire.com: https://www.businesswire.com/news/home/20260302267114/en/
Contacts
For more information, please contact:
Daniela Guerriero
Marketing & Communications Manager
Phone +41.91.850 5050
dguerriero@linnea.ch
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AppLogic Networks Completes Live Trial at JANOG57 in Osaka, Powering New AI-Driven Dashboards to Enhance NOC Team’s Capabilities3.3.2026 10:00:00 EET | Press release
AppLogic Networks today announced the results of a live trial deployment at JANOG57 in Osaka, where the JANOG Network Operations Center (“NOC”) team used AppLogic Networks data for real-time monitoring, troubleshooting, and experience reporting during the event. The trial showcased an Elevated Observability approach that goes beyond traditional monitoring by adding B.E.S.T. insights (Behavior, Experience, Sentiment, and Trends) that help teams make faster decisions, reduce guesswork, and support new services in high-demand environments. Hosted by SAKURA internet Inc., JANOG57 is one of Japan’s largest operator conferences that brings together thousands of attendees, dozens of sessions, and more than 100 booths. AppLogic Networks participated as an infrastructure supplier, supporting the NOC team alongside other technology vendors. AI-driven experience scoring powered by AppLogic Networks data During the event, the NOC team streamed AppLogic Networks data into Grafana and quickly built
Transforming Africa’s Future Farmers: Satellite-Enabled IoT Powers Data-Driven Agribusinesses3.3.2026 09:50:00 EET | Press release
SES, a leading space solutions company, along with IoT technology provider Advannotech and additional service providers are collaborating to bring technology to South Africa’s next generation of farmers. The project would enable young farmers to get a feel for data-driven agribusiness while participating in the Enterprising Africa Regional Network (EARN), a hands-on program combining practical farming, business skills and innovation for success. The program aims to leverage technology to tackle food insecurity and economic growth through a climate-smart training farm in Centurion, South Africa and has successfully completed a three-month proof-of-concept trial. Using IoT over satellite and LoRaWAN (Long Range Wide Area Network) sensors, the project monitors soil moisture and temperature, water levels, and environmental factors such as light, CO₂, humidity and air temperature. Connected through SES satellites to a cloud-based backend, this system bypasses cellular networks to deliver co
Quectel Expands Small Cell Antennas Portfolio With Five New Products3.3.2026 09:00:00 EET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, has introduced five new small cell antennas to add further functionality and provide greater flexibility and choice for customers designing and implementing small cell deployments. The new antennas bring an additional range of form factors, mounting options and performance characteristics to the Quectel antenna range. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302915004/en/ Quectel expands small cell antennas portfolio with five new products “Whether you’re looking for an antenna to support critical wireless communications, dense stadium usage scenarios or ultimate capacity, these five new Quectel antennas have been designed to meet your needs,” says David Wei, Antenna Product Head, Quectel Wireless Solutions. “The new antennas augment our already comprehensive range of antennas, bring further choice and add capabilities for developers and enginee
Quectel Introduces FGH200M Wi-Fi HaLow Module for massive IoT Deployments3.3.2026 09:00:00 EET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of the FGH200M long range, low power Wi-Fi HaLow module. Based on the Morse Micro MM8108 chipset and operating in the sub-1GHz license exempt frequency band, the module delivers enhanced penetration and broader coverage, over a range of approximately 1km, while supporting low power consumption and large-scale device connectivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302200601/en/ Quectel introduces FGH200M Wi-Fi HaLow module for massive IoT deployments The FGH200M module adopts the IEEE 802.11ah wireless networking protocol, also known as Wi-Fi HaLow, operating in the license-exempt Sub-1GHz spectrum. Designed to meet the evolving requirements of IoT connectivity, the FGH200M delivers extended Sub-1GHz signal coverage, enabling reliable device control at distances of up to one kilometer. “We’re excited to unveil th
Meiji Seika Pharma’s Morcamilast (ME3183) was Granted Orphan Medicinal Product Designation by the European Commission for Palmoplantar Pustulosis3.3.2026 03:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodiesterase-4 (PDE4) inhibitor, has been granted orphan medicinal product designation by the European Commission (EC) for the treatment of palmoplantar pustulosis (PPP). Palmoplantar pustulosis is a chronic inflammatory disease characterized by the development of multiple sterile pustules on the palms and soles. Patients often experience pain and pruritus of the skin, and the condition can be accompanied by nail involvement and joint pain. Because lesions on the palms are visible to others and lesions on the soles can cause pain while walking, daily functioning can be significantly restricted, leading in a substantial reduction in quality of life. PPP has a pathophysiology distinct from psoriasis and pustular psoriasis, and treatment can be challenging, unde
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom